We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Auctioneer Bill

12 November 2014 By Robert Cyran

The hedgie will do well from kicking off a sale of Allergan. But doing the same for Zoetis will be harder. Pfizer found no takers before it spun off the unit in 2013. It’s not clear why potential buyers – even Valeant, Ackman’s Allergan partner – would now pay twice as much.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)